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ABSTRACT:Melt blowing (MB) was investigated to prepare a fast dissolving fibrous drug-loaded solid dispersion and compared with solvent-
based electrospinning (SES) and melt electrospinning (MES). As a conventional solvent-free technique coupled with melt extrusion and
using a high-speed gas stream, MB can provide high-quality micro- and nanofibers at industrial throughput levels. Carvedilol, a weak-base
model drug with poor water solubility, was processed using a common composition optimized for the fiber spinning and blowing methods
based on a hydrophilic vinylpyrrolidone-vinyl acetate copolymer (PVPVA64) and PEG 3000 plasticizer. Scanning electron microscopy
combined with fiber diameter analysis showed diameter distributions characteristic to each prepared fibrous fabrics (the mean value
increased toward SES<MB<MES). Differential scanning calorimetry and X-ray diffraction studies revealed that the incorporated drug was
in amorphous form regardless the preparation method. The HPLC studies demonstrated that all of the materials produced by the different
techniques passed the regulatory purity requirements. The fibers exhibited ultrafast drug release tested under neutral pH conditions; the
melt-blown sample dissolved within 2 min owing to its large specific surface area. The presented results confirm the applicability of MB
as a novel formulation technique for polymer-based drug delivery systems. C© 2015 Wiley Periodicals, Inc. and the American Pharmacists
Association J Pharm Sci
Keywords: electrospinning; melt electrospinning; melt blowing; extrusion; oral drug delivery; solid dispersion; enhanced dissolution rate;
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INTRODUCTION
In recent years, solvent-based electrospinning (SES) has been
found to be a new and effective formulation technique to pro-
duce amorphous solid dispersions for controlled delivery of
the active pharmaceutical ingredients (APIs).1 SES involves
a high-voltage electrostatic field used to draw fibers reaching
submicronic diameters from a viscous solution leading to an
amorphous solid solution of the API incorporated in the poly-
meric matrix. Among the drug-loaded electrospun fibers pre-
sented so far,2–7 applications for gastrointestinal delivery with
enhanced drug release rates are the most promising as there
is an increasing number of drugs with poor water solubility,8,9
that is, with insufficient bioavailability at peroral administra-
tion (which is themost popular route because of the simplicity of
taking and good patient compliance).10,11 The huge surface area
of the nanofibers according to the Noyes–Whitney equation12 as
well as the increased solubility of the amorphous drug formed
during the uniquely fast (t < 0.1 s)13 SES process both result in
improved dissolution of the poorly soluble drug. Moreover, SES
can be conducted at room temperature in a gentle way with low
power consumption avoiding problems related to other tech-
niques to produce solid dispersions. In turn, freeze-drying is an
energy-intensive technology with long processing time periods,
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whereas spray drying can produce only larger micronic parti-
cles from a more diluted solution using a heated air stream.
However, the use of organic solvents to conduct solvent-based
techniques also involves the risk of explosion (i.e., explosion
proof design is required), the need of tail gas cleaning and the
probability of undesired toxic solvent residue in the product.
The solvent-free “green” variant of electrospinning, melt
electrospinning (MES), is also capable to produce fibers from
a polymer melt obtaining large surface area with fast drug re-
lease rates.14 In this case, the preparation of the melt and the
amorphization of the API occur preferably during melt extru-
sion, a widely investigated continuous tool having been applied
for commercialized pharmaceutical products as well.15–21 The
integration of MES into melt-extrusion technology line can be
a viable continuous tool to produce solid dispersions with high
surface area in one single step.
Despite the advantageous properties, both SES and MES
have their own limitations. Although there have been attempts
for process scale-up, both for MES22,23 and particularly for
SES applying a needleless (free surface) configuration,24–26 the
achievable productivity is moderate compared with other fiber
production techniques,27 and the use of volatile solvents seems
to complicate the intensification because of the undesired dry-
ing of the free solution surface. Although MES can eliminate
all the technological problems related to solvents mentioned
above, only fibers of several tens of micrometers are achievable
owing to the high-melt viscosity.28
A conventional fabrication method of micro- and nanofibers
is melt blowing (MB) where a polymer melt is extruded through
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small nozzles surrounded by high-speed blowing gas.29 The first
research on MB was a naval attempt to produce fine filtra-
tionmaterials for radiationmeasurements on drone aircrafts in
the 1950s.30 Later on, Exxon Corporation developed an indus-
trial process based on the MB principle with high-throughput
levels.31 MB appears to be a promising technique to prepare
drug-loaded fibers combining the advantages of SES, MES, and
thus, melt extrusion accompanied with excellent productivity.
However, MB has not been used yet for preparing drug delivery
systems.
In the work outlined in this paper, a comparison has been
made between the referred three fiber formation techniques,
SES, MES, and MB with the same composition to improve the
dissolution characteristics of the poorly water-soluble model
drug carvedilol (CAR). As melt extrusion served the input for
MES and MB, it was also involved as a reference method. Ac-
cording to our previous reports, drug-loaded MES fibers can
be produced using a polymer (Eudragit R© E) soluble at acidic
pH.14,32 Now, our aim was selecting a polymeric matrix that
ensures enhanced dissolution at neutral pH as well, in which,
however, the solubility of the weak-base CAR is lower than
in acidic media.33 Developing such a formulation is of a great
therapeutic importance considering that the normally acidic
gastric pH can be shifted toward neutral values because of var-
ious factors,34 for instance, the ingested food,35 disorders (e.g.,
AIDS),36 medication (e.g., antacids, proton-pump inhibitors,H2-
receptor antagonists),37,38 or the residence time in the stomach
can be very short (even 15 s) when the solid dosage form is taken
into an empty stomach.39 After finding and processing the ap-
propriate composition, besides characterization of the morphol-
ogy, the physical state of CAR and the dissolution kinetics of
the samples, impurity measurements were also performed to
assess the degrading effect of the different methods on the API.
MATERIALS AND METHODS
Materials
Carvedilol (free base; Fig. 1a) from Sigma–Aldrich (Budapest,
Hungary) with purity 99% was used as API. PVPVA64
(Kollidon R© VA 64; Fig. 1b) was kindly provided by BASF (Lud-
wigshafen, Germany), which is an N-vinylpyrrolidone-vinyl ac-
etate amorphous copolymer (1.2:1 molar ratio, i.e., 6:4 mass ra-
Figure 1. The structure of (a) CAR and (b) PVPVA64.
tio), with an average molecular weight of 45–70 kDa. Polyethy-
lene glycols (PEGs) (average molecular weights: 1500 and 3000
Da, respectively) were used as additives from Sigma–Aldrich.
Solvent-Based Electrospinning
The solvent-based electrostatic spinner used for the exper-
iments was equipped with NT-35 high-voltage DC supply
(MA2000; Unitronik Ltd., Nagykanizsa, Hungary). The elec-
trical potential applied on the spinneret electrode was 25 kV.
A grounded aluminum plate covered with aluminum foil was
used as collector. The distance of the spinneret and the collec-
tor was 20 cm and the experiments were performed at room
temperature. Fibers could be readily formed from an ethano-
lic PVPVA64 solution; however, addition of dichloromethane
(DCM) was required to dissolve PEGs and dimethylformamide
(DMF)was also introduced as a fiber thinning agent. Thus, 2.5 g
PVPVA64 was dissolved in 4 mL of an ethanol–DCM–DMF
(5:1:4) ternary mixture while stirred without heating; the PEG
and the API were added subsequently. The solution was dosed
by a SEP-10S Plus type syringe pump (Aitecs, Vilnius, Lithua-
nia) with a dosing rate of 4 mL/h.
Melt Extrusion
Extrudates containing CARwere prepared byHAAKEMiniLab
micro compounder (Thermo-Haake, Karlsruhe, Germany). A
certain amount of PVPVA64 and CAR (10%) was mixed well
with and without PEG and the mixture was introduced into
the hopper of the miniextruder. The rotation speed was fixed at
100 rpm; the temperature was 120°C without PEG and 110°C
when PEG was applied. The obtained extrudates were ground
in a mortar and sieved (size: 400 :m).
Melt Electrospinning
The solid dispersion prepared by melt extrusion was fed into
MES equipment, which was designed and built at Department
of Organic Chemistry, Budapest University of Technology and
Economics (Budapest, Hungary). The MES equipment (Fig. 2a)
has two temperature-controlled zones and a programmable
feeder. The applied feeding rate was 1 mL/h and the tem-
perature of the feeding unit (TB) was similar to that of melt
extrusion. The spinneret temperature (TA) determination was
supported by oscillatory rheology measurements (see section
“Results and Discussion”). The distance of the spinneret and
the collector was 10 cm. The stainless steel metal syringe is
Figure 2. The schematic drawing of the two-zone-heated stainless
steel metal syringe coupled (a) with a MES or (b) a MB spinneret.
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Table 1. Composition, Production Parameters, Diameter Analysis, and Specific Surface Area of the Samples
Production Process SES MES MB Extrusion
CAR (mass, %) 10 10 10 10
PVPVA64 (mass, %) 75 75 75 75
PEG 3000 (mass, %) 15 15 15 15
Peak temperature (°C) 25 145 145 110
Flow rate (mL/h) 4 1 1 80
Output on laboratory scale (g/h) 1.8 1.2 1.2 96
Mean fiber or particle diameter (:m, ±SD) 1.8 ± 0.3 45.9 ± 11.3 9.4 ± 2.2 300a
Lognormal distribution fit : 0.593 3.797 2.219 –
F 0.179 0.250 0.229 –
R2 0.9665 0.9129 0.9488 –
Specific surface area (m2/g)b 1.81 0.07 0.35 0.017
aEstimated based on SEM images.
bCalculated from mean fiber or spherical particle size.
easy to clean; the spinneret part is dismountable and the capil-
lary tube can be replaced for a new experiment, if it is needed.
Melt Blowing
The MB experiments were performed similarly to MES, the
feeding unit was the same, which was equipped with a newly
designed MB head (Fig. 2b), and an external gas-heater unit
and further devices were attached to maintain and monitor the
gas supply of the blowing process. Thus, the feeding tempera-
ture (TB) was similar to that of melt extrusion, and the same
nozzle temperature (i.e., blowing gas temperature, TGAS) and
polymer feeding rate were applied as during MES (Table 1).
The airflow was supplied by an oil-free membrane compressor
(SF 1 FF; Atlas Copco, Stockholm, Sweden) and was controlled
by manual feedback on the MB head pressure that was main-
tained at 1.6 bar. Although the volumetric flow of the input cold
air stream could be determined using a rotameter (12 L/min),
the air speed through the MB coaxial capillary tube was calcu-
lated based on the measured static pressure and temperature
in the chamber because the flow is considered to be compress-
ible with Mach numbers (the ratio of the actual and sonic ve-
locity) greater than 0.3.40 Assuming an isentropic expansion
of an ideal gas, the measured 1.6 bar absolute pressure in the
MB head resulted in an air speed of 325 m/s (Mach number of
0.85) at the exit of the orifice. For the collection of the fibers, a
basket with vents was placed 30 cm away from the MB head.
As the basic structure of the MB nozzle was similar to that of
the MES nozzle, the cleaning and replacement of the internal
needle could be easily performed.
Scanning Electron Microscopy and Fiber Diameter Analysis
Morphology of the samples was investigated by a JEOL
6380LVa (JEOL, Tokyo, Japan) type scanning electron micro-
scope. Each specimen was fixed by conductive double-sided car-
bon adhesive tape and sputter-coated with gold prior to the
examination. Applied accelerating voltage and working dis-
tance were 15–30 kV and 10 mm, respectively. A randomized
fiber diameter determination method was developed based on
scanning electron microscopy (SEM) imaging. Ten images were
taken of each prepared fiber population, then, on each image,
random points were marked by a short program written in
C++ (Visual Studio Express 2008; Microsoft, Redmond, Wash-
ington). At these points, the diameters (where possible; n = 10
for each image, n = 100 for each sample) and also the scale
bars of the SEM images for reference were drawn manually us-
ing a vector graphics editor (Inkscape). Another C++ program
was written and used to evaluate the drawn diameters quickly
and convert into a text file. Lognormal distribution fitting was
calculated using Statistica v10 (StatSoft, Tulsa, Oklahoma).
Differential Scanning Calorimetry
Differential scanning calorimetry (DSC) measurements were
carried out using a TA Instruments Q2000 DSC apparatus
(New Castle, Delaware) (sample weight: 2–3 mg, closed alu-
minum pan, 50 mL/min nitrogen purge gas). The temperature
program consisted of an isothermal period, which lasted for
1 min at −30°C, with subsequent linear heating from −30°C to
200°C at the rate of 10°C/min. Purified indium standard was
used to calibrate the instrument.
X-ray Diffraction
Powder X-ray diffraction (XRD) patterns were recorded by a
PANanalytical X’pert Pro MDP X-ray diffractometer (Almelo,
The Netherlands) using Cu-K" radiation (1.542 A˚) and Ni filter.
The applied voltage was 40 kV, whereas the current was 30mA.
The untreated materials, physical mixture (mixed in a mortar
by a pestle), fibers, and extrudate were analyzed for angles 22
between 4° and 42°.
Rheology
Viscosity measurements as a function of temperature were car-
ried out of the extruded samples using an AR 2000 Rotational
Rheometer (TA Instruments) in oscillating mode with a paral-
lel plate configuration. The upper moved portion was a 40-mm
diameter steel plate and the lower portion was a Teflon-coated
Peltier plate. The extruded samples were placed on the pre-
heated Peltier plate and melted. The upper plate was then low-
ered to the gap of 500 :m. The controlled variable was the
oscillating torque, oscillatory tests were carried out at 1000
:Nm torque and 1 Hz frequency, and dynamic stress sweep
tests confirmed that themeasurements weremade in the linear
viscoelastic region. The temperature was ramped down from
180°C to 100°C with a linear rate of 5°C/min. Frequency sweep
tests were carried out under the same circumstances with se-
lected extrudates at an appropriate melting temperature be-
tween 0.01 and 100 Hz oscillation frequency. The tests were
carried out in triplicate.
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HPLC Studies
Chemical stability of CAR during the formulation process was
determined through analyzing the decomposition byproducts
using RP-HPLC (Agilent 1200 series LC System; Santa Clara,
California). A gradient elution of 0.1M phosphoric acid and ace-
tonitrile was performed at a flow rate of 1.0 mL/min and 25°C
started at 25% acetonitrile, increased linearly to 60% over 40
min and maintained for 5 min, then returned to the initial com-
position over 10 min. The UV detection wavelength was set to
285 nm. The pure API, the extruded, and fibrous samples were
dissolved in the initial mobile phase of gradient elution obtain-
ing an 1 mg/mL solution of CAR; 20 :L of this stock solution
were injected onto the column [Phenomenex Luna C18 column
(5 :m; 150 × 4.6 mm); Torrance, California]. The amount of
the degradation products was determined based on the peak
areas. The absorption coefficients of the byproducts are higher
than that of the pure CAR,41 which precludes the underesti-
mation of the concentration of the degradation products. The
chromatography tests were performed in triplicate.
In Vitro Dissolution Measurement
The dissolution studies were performed using a Pharmatest
PTWS 600 dissolution tester [USP II apparatus (paddle); Hain-
burg, Germany]. Samples equivalent to 12.5 mg of CAR were
added directly in the dissolution vessel containing 900 mL pH
6.8 100 mM phosphate buffer prepared according to USP. Fi-
brous samples were used for dissolution tests as spun. The tem-
perature was maintained at 37 ± 0.5°C and stirred at 100 rpm.
Samples (5mL)were filtered (0.45 :mmembrane) and collected
periodically, and the concentration of CAR was determined by
UV spectrophotometry at 242 nm (Agilent 8453 UV–Vis spec-
trophotometer; Palo Alto, California). Percentage of dissolution
was readily calculated according to the calibration curves of
CAR in pH 6.8 phosphate buffer because of the lack of absorp-
tion peaks of the applied excipients in this range.
RESULTS AND DISCUSSION
Adjustment of the Composition
Among the pharmaceutically applicable polymers, which are
well soluble at acidic as well as neutral pH values, there are a
limited number of compounds suitable for fiber formation both
from solution and melt. In order to compare the three fiber for-
mation processes (MB, MES, and SES), a common composition
was required. However, the main bottleneck of finding an ap-
propriate polymer was found to be the high melt viscosity that
prevents drawing a fibrous material exploiting the attraction
force of the electrostatic field. The viscosity range required for
MES is 100–200 Pa s or less.28
Oscillatory viscosimetry was applied to determine the effect
of the composition on the melt properties (Fig. 3a). The selected
PVPVA64 polymer of high water solubility and glass transi-
tion temperature of around 107°C42 has a high melt viscosity
in unmodified form (even at extremely elevated temperatures),
which means a challenge for fiber formation. The incorpora-
tion of 10% of the model drug (CAR) into the polymer matrix
resulted in advantageous drop of viscosity; however, it was not
enough for reaching the desired range for MES (i.e., below 100–
200 Pa s) at a satisfactorily low temperature. One way to over-
come this difficulty is to further increase the mass percentage
Figure 3. (a) Complex viscosity of (I) pure PVPVA64 and PVPVA64-
based solid dispersions with (II) 10%CAR or 10%CAR and (III) 5%, (IV)
10%, and (V) 15% PEG 3000, respectively, as a function of temperature
(T= 1Hz). (b) Complex viscosity of PVPVA64+10%CAR+15%PEG3000
blend at 145°C as a function of increasing dynamic frequency.
of the API. Nevertheless, higher loadings of the drug may have
a well-known hydrophobization side effect that can unfavorably
lower the dissolution rates.43 According to our earlier experi-
ences, even a composition containing 20% CAR using a more
plastic carrier (Eudragit R© E) could have been melt electrospun
at a relatively high temperature.14 Thus, instead of increasing
the API concentration, a hydrophilic plasticizer was introduced
into the PVPVA64–CAR dispersion in order to lower the pro-
cess temperature. Low-molecular-weight semicrystalline PEGs
are an efficient plasticizing agent, whereas the handling of the
product and drug release is not influenced negatively. Concen-
tration levels of 5%, 10%, and 15% of PEG 3000 were evaluated
in regard of the dependence of melt viscosity over temperature.
The logarithmic viscosity curves were closely straight and par-
allel indicating the good mutual miscibility of the components
in melt at elevated temperatures, which was also evidenced
by the yellowish transparent appearance of the prepared bi-
nary and ternary blends using the melt-extrusion technique.
Although 5% and 10% of PEG could not provide the desired
plasticizing efficiency, the PVPVA64+10%CAR+15%PEG3000
composition showed low-enough viscosity for MES at an accept-
able temperature of TA = 145°C (Fig. 3a, curve V).
It must be noted that blends composed with lower molecular
weight PEGs (e.g., the semisolid PEG 1500) resulted in a sticky
and hygroscopic material, whereas the more crystalline PEG
3000 has eliminated those problems.
Fiber Morphology and Diameter Analysis
In good accordance with the oscillatory viscosity measure-
ments, the optimized blend containing PVPVA64 as a carrier
and fiber former, 10% API and 15% PEG as plasticizer, was
successfully melt electrospun with diameters of 30–60 :m at
the predicted 145°C nozzle temperature (Fig. 4a). However, the
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Figure 4. Scanning electron microscopic images of (a) crystalline CAR and PVPVA64-based (b) melt electrospun fibers, (c) solvent-based
electrospun fibers, (d) melt-blown fibers, and (e) ground extrudate containing similarly 10% CAR and 15% PEG 3000.
MES experiments showed that the observable vigorous move-
ment of the molten jet (which contributes to fiber thinning44)
slowed down when the nozzle was slightly colder (5°C) as the
viscosity depended on the temperature quite sensitively.
The SES could also produce a good quality mat composing
from the identical polymer–drug–plasticizer mixture. Though
the presence of PEG 3000 necessitated additional optimization
on the polymer concentration in the solution and the organic
cosolvent itself (see section “Materials and Methods”), bead-
free fibers were obtained with diameters of around 2 :m, but
submicronic fibers were also observable (Fig. 4b).
The morphology of the drug-loaded melt-blown sample is
presented in Figure 4c. The MB experiments were conducted
under the same circumstances (i.e., 1 mL/h, 145°C spinneret
or air stream temperature) as MES except that not an elec-
trostatic field but a high-speed air stream was used to form
the fibers. The calculated air velocity at the exit of the orifice
was 325 m/s, 0.85-fold of the actual sonic velocity. Continuous
fiber formation was observable during the blowing process us-
ing PVPVA64 as a matrix. The diameters of the MB fibers were
around 5–15 :m implying that the blowing force considerably
exceeds the impact of the electrostatic field used at MES un-
der the same circumstances. Although the feeding rate of the
MB experiments was slow, an industrial MB die can have a
satisfying throughput maintaining excellent fiber morphology.
It is known that electrospinning techniques45 aswell asMB46
produce fibers with lognormal diameter distribution. Fitting a
lognormal probability distribution on the measured diameters
yields the location parameter (:) and the scale parameter (F)
that can be used to compare the predicted populations on a log-
arithmically scaled abscissa obtaining symmetrical bell curves
(i.e., apparently normal distributions).
As it can be seen in Figure 5, the diameter distributions of
the fibers produced by the three different techniques are very
well separated as either the initial viscosity or the type of the
drawing force distinctly differ. Electrospinning from solutions
can produce submicronic fibers because of the lower viscosity
and intense movement of the jet-promoting elongation of poly-
mer chains, whereas when electrospinning frommelts with one
order of magnitude larger viscosity, fibers usually in excess of
10 :m are achievable. In contrast to MES, MB is capable of
producing fibers even with average diameters of 1–2 :m, but
the submicronic range can also be reached.31,46 The force of the
high-velocity air exerted on the surface of the polymer melt
offers greater stretching compared with the high-voltage elec-
trostatic field. Further reason of the fivefold difference in av-
erage fiber diameter between the drug-loaded MES and MB
samples could be a decreased viscosity value at higher shear
rates (thixotropy). The dynamic frequency sweep tests showed
negligible deflection at high shear rates in Figure 3b; however,
the shear rate occurring during MB can exceed several orders
of magnitude the measuring range of a rheometer.31 The width
of the fitted peaks of diameter distribution varies slightly on
the logarithmic scale: SES fibers have the narrowest and MES
fibers have the widest distribution. The wider relative devia-
tions of the MES diameters may be because of the aforemen-
tioned sensitive dependence of the viscosity on the temperature,
the effect of which could not be completely eliminated by the
moderate electrostatic force.
From a pharmaceutical point of view, fibers with smaller di-
ameters exhibit larger specific surface area that can be advan-
tageous for dissolution enhancement according to the Noyes–
Whitney equation. Furthermore, the differences in the basic
principles between the fiber formation techniques leading to
significant variation inmean diametersmay also have a notable
effect on the physicochemical properties of the solid dispersions
(see Table 1 for further details about the samples).
Differential Scanning Calorimetry
In order to investigate the physical state of the API and the
excipients, DSC measurements were performed (Fig. 6).
The physical mixtures of PVPVA64 and 5% CAR as well
as PEG 3000 and CAR (5:1 mass ratio) served as references;
the melting peak of the crystalline CAR at 117°C was clearly
detectable. The weak change in the specific heat belonging to
the glass transition of the pure PVPVA64was barely observable
next to thewide endothermic peak ofwater loss; PVPVA64 has a
glass transition temperature (Tg) of 107°C.42 The melting point
of PEG3000 could easily bemeasured at 60°C; crystalline PEGs
have particularly high enthalpy of fusion (almost two-thirds of
that of water).47
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Figure 5. Normalized lognormal distribution fits to logarithmic diameter for PVPA64-based fibrous samples containing 10% CAR and 15%
PEG 3000, prepared by SES, MB, and MES, and histograms of the measured diameters (n = 100).
The thermograms of the common composition processed by
three different fiber formation techniques and melt extrusion
did not show the melting peak of CAR; the drug turned into
an amorphous form in each case. The applied techniques have
different drug amorphizationmechanisms. SES can gently turn
the API into an amorphous form by the ultrafast evaporation
of the solvent. The high shear forces during extruded and the
elevated temperatures followed by a quick cooling, especially
at MES and MB, are also in favor of drug amorphization.
The crystalline behavior of PEG could not be fully termi-
nated by the amorphization forces described above. Besides the
distributed part of PEG, small segments of PEG chains could
organize during solidification in a folded state. Those ordered
PEG segments provided rigidity to the dispersions leading to
better processibility (grindability). The melting of the ordered
PEG segments can be used to draw conclusions from the dis-
persions. The solvent-based electrospun sample had the highest
PEG melting temperature (59°C) and the raw-extruded mate-
rial had the lowest (52°C). During solution electrospinning, the
solidification of the PEG content may have an increased rate
as DCM, in that case the only compatible solvent with PEG,
evaporates quickly, leading to somewhat better organized PEG
chains of highermelting temperature. In turn, the viscousmelt,
the intense mixing and the fast cooling during the extrusion
process kept the well-distributed PEG chains in contact with
larger amount of other components, that is, a lowered melting
point could be observed. Melt extrusion also served the input
material for MES and MB, but during the heating period with-
out mixing some relaxation could occur within the PEG phase,
similarly elevated melting points could be measured (58°C).
X-ray Diffraction
X-ray diffraction was used to analyze the prepared solid dis-
persions in regard of crystallinity of the drug and the applied
excipients the result of which is shown in Figure 7.
The physical mixture of 5% crystalline CAR and PVPVA64
served as a reference; the sharp and most intense diffrac-
tion peaks of CAR were still detectable emerging from the
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Figure 6. Differential scanning calorimetry thermograms of the pure
PVPVA64, physical mixture of PVPVA64, and 5% CAR, physical mix-
ture of PEG 3000 and CAR (5:1), and the extruded, MES, MB, and SES
samples containing similarly 10% CAR and 15% PEG 3000.
amorphous background of PVPVA64. The diffraction pattern of
PEG 3000 showed two main peaks at 22= 19.3° and 23.5°. The
solid dispersions prepared by different techniques did not show
any sign of crystallinity regarding the drug compound confirm-
ing the amorphous state of CAR also confirmed by DSC. How-
ever, the crystallinity of the PEG content appeared to be not so
intense in the X-ray diffractograms of the samples in contrast
to the DSC results evidencing the presence of small ordered
PEG segments. Only weak humps were observable, stemming
from the aforementioned main peaks of PEG 3000 with slight
differences between the extrudate and the fibers.
RP-HPLC Studies
Reversed-phase high-performance liquid chromatography cou-
pled with UV detection was applied to determine the amount of
the degradation products of CAR in the prepared solid disper-
sions. As a starting point, the current ICH guideline of impu-
rities in new drug products describes the relevant limits of the
degradation products.48 The absolute maximum dose of CAR is
2× 50 mg daily,49 thus the limits for each degradation products
are as follows: reporting threshold—above 0.1%; identification
threshold—above 0.2%; qualification threshold—above 200 :g
(in this case it equals to 0.2% aswell). In contrast, the European
Pharmacopoeia (Ph. Eur.) specifies a total impurity threshold
of 0.5% in products containing CAR.50
Despite that CAR can be labeled as a thermosensitive com-
pound when it is amorphized,32 solid dispersions of high pu-
rity could be prepared even after using different melting meth-
ods. According to the impurity tests, crystalline CAR contained
small amounts of impurities (0.07 ± 0.01%). Turning CAR into
an amorphous form using the gentle SES had practically no
effect on the purity of the formulation (0.08 ± 0.01%). In turn,
the applied melting methods increased noticeably the amount
of the degradation products. The melt-extrusion step led to a
0.18 ± 0.02% total impurity, whereas further processing into
melt electrospun and melt-blown fibers also had an additional
thermal impact resulting in a 0.24 ± 0.02% (MES) and 0.27
± 0.02% (MB) total impurity. Thus, none of the prepared solid
dispersions exceeded the total impurity threshold of Ph. Eur.
and there were no individual degradation products beyond the
ICH identification threshold (0.2%) based on the recorded chro-
matograms.
Figure 7. X-ray diffraction patterns of crystalline CAR, physical mixture of PVPVA64 and 5% CAR, PEG 3000, and the extruded, MES, MB,
and SES samples containing similarly 10% CAR and 15% PEG 3000.
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Although fiber formation from melt (MES, MB) had a sig-
nificant additional degrading effect, it must be noted that by
direct fiber formation through an optimized high-throughput
spinneret the level of the concerned extra contamination can
bemuch less. Note that the chromatographymeasurements did
not reveal any newly eluted peak when comparing EX, MES,
and MB. During MB, despite the intense biphasic exposure
(molten polymer and hot air), the polymeric matrix seems to
have a protective effect on the API from the oxidative stress
(considering that CAR is mildly prone to degradation in a per-
oxidic medium51).
In Vitro Dissolution
The enhanced drug release properties of the fibrous samples
and the ground extrudate were analyzed compared with the
poorly soluble crystalline API (Fig. 8).
Carvedilol is a weak-basic compound having a limited sol-
ubility at both acidic and especially neutral pH values; thus,
an increased dissolution rate is a rather challenging formu-
lation task when tests are carried out in a pH 6.8 medium.
Despite this, the prepared PVPVA64-based solid dispersions
with 10% CAR and 15% PEG 3000 exhibited ultrafast drug dis-
solution. In contrast to that, only 10% of the crystalline CAR
with particles of 10–50 :m size range (Fig. 4a) was dissolved
after 20 min and 20% after 1 h. In accordance to the Noyes–
Whitney equation, the fastest dissolution speeds belong to the
fibrous samples with large specific surface areas, in these cases
less than 5 min were needed for total drug release. However,
the SES sample with the smallest average fiber diameter and
thus the largest surface area showed a somewhat moderate
dissolution compared with MB and MES. The reason for this
seemingly unexpected phenomenon lies in the different acces-
sibility of the fibers by the dissolution media.14 The MES and
MB fibers could be collected loosely, that is, with high poros-
ity, whereas SES generated a thick fibrous mat with tightly
packed fibers, thus the huge surface area could not be fully
exploited during the dissolution process. Although MES and
MB fibers also had a fivefold ratio in the specific surface area
Figure 8. Dissolution profiles of CAR [12.5 mg dosage, 900 mL pH
6.8, USP Dissolution Apparatus 2 (paddle), 100 rpm, 37°C]. PVPVA64-
based extruded, MES, MB, and SES samples containing similarly 10%
CAR and 15% PEG 3000; unprocessed crystalline CAR. The error bars
indicate the standard deviations (n = 3).
in favor of MB, the dissolution characteristics were similar,
which can be attributed to the somewhat limited distribution
of the cotton-wool-like MB samples in the dissolution vessel,
as opposed to the thicker and more brittle MES fibers. The
ground extrudate showed significantly slower dissolution in
contrast to the fibrous samples owing to the larger particle
sizes, whereas the almost total drug release could be mea-
sured after 15 min. The results confirm the great efficiency
of the combination of polymer-based solid dispersions with
an increased specific surface area, and also imply the impor-
tance of understanding the effect of the wetting characteristics
(e.g., the porosity as a result of the macroscopic structure of
the mat) of drug-loaded fibrous materials on the dissolution
behavior.
CONCLUSIONS
Three different fiber formation techniques, SES, MES, andMB,
were used to prepare PVPVA64-based fast-dissolving mats to
enhance the dissolution characteristics of the poorly water-
soluble CAR. Viscosity was found to be a key condition to pro-
duce melt electrospun fibers; thus, the final common compo-
sition used for comparison was optimized based on oscillatory
viscosimetry; 15% PEG 3000 had appropriate plasticizing effect
in the presence of 10% API. MB was successfully performed
under the same thermal and feeding circumstances as MES
but using a high-speed air stream. The SEM images coupled
with fiber diameter analysis revealed well-separated diameter
distributions; the average diameters increased toward solvent-
based electrospun<melt-blown<melt electrospun fibers. DSC
and XRD did not show any crystallinity belonging to CAR in the
extruded and fibrous samples. Puritymeasurements showed an
acceptable impurity content in the samples prepared by melt-
ing methods including MB, whereas SES had practically no
degrading effect. Fast drug release of the weak-base CAR could
be measured at neutral pH in the case of the fibers; significant
improvement could be achieved compared with the crystalline
API. Further steps to obtain typical solid dosage forms (e.g.,
compressed tablets) using the PVPVA64+PEG3000-based solid
dispersions is facilitated by the good processibility (grindabil-
ity) of the rigid solid dispersion and the subsequentmixing with
other excipients.
The results demonstrate that the industrially available MB
is a promising technique to produce drug-loaded polymeric
mats with modified drug release properties. Further investi-
gations are required to test the processibility of other phar-
maceutically applicable polymers via MB. Inertisation of the
blowing process can be also a relevant technology issue when
the API is highly sensitive to an oxidative stress.
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